Nothing Special   »   [go: up one dir, main page]

CY1122403T1 - Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης - Google Patents

Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης

Info

Publication number
CY1122403T1
CY1122403T1 CY20191101244T CY191101244T CY1122403T1 CY 1122403 T1 CY1122403 T1 CY 1122403T1 CY 20191101244 T CY20191101244 T CY 20191101244T CY 191101244 T CY191101244 T CY 191101244T CY 1122403 T1 CY1122403 T1 CY 1122403T1
Authority
CY
Cyprus
Prior art keywords
chlorokynurenine
dosage forms
therapeutic uses
dopa
compositions
Prior art date
Application number
CY20191101244T
Other languages
English (en)
Inventor
Ralph H. Snodgrass
Allen E. Cato
Jack S. Hicklin
Original Assignee
Vistagen Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vistagen Therapeutics, Inc. filed Critical Vistagen Therapeutics, Inc.
Publication of CY1122403T1 publication Critical patent/CY1122403T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Lubricants (AREA)
  • Quinoline Compounds (AREA)

Abstract

Προβλέπονται συνθέσεις της L-4-χλωροκυνουρενίνης, όπως και μέθοδοι για τη θεραπεία της νευρολογικής δυσλειτουργίας, συγκεκριμένα της κατάθλιψης και των δυσκινησιών που σχετίζονται με L-DOPA.
CY20191101244T 2013-01-22 2019-11-27 Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης CY1122403T1 (el)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361849191P 2013-01-22 2013-01-22
PCT/US2014/012598 WO2014116739A1 (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses l-4-chlorokynurenine
EP14743570.5A EP2948140B1 (en) 2013-01-22 2014-01-22 Dosage forms and therapeutic uses l-4-chlorokynurenine

Publications (1)

Publication Number Publication Date
CY1122403T1 true CY1122403T1 (el) 2021-01-27

Family

ID=51228003

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20191101244T CY1122403T1 (el) 2013-01-22 2019-11-27 Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης

Country Status (22)

Country Link
US (7) US9993450B2 (el)
EP (4) EP3598971B1 (el)
JP (5) JP6436913B2 (el)
KR (5) KR102335919B1 (el)
CN (4) CN112933073A (el)
AU (4) AU2014209466B2 (el)
BR (1) BR112015017535A2 (el)
CA (3) CA2898619C (el)
CY (1) CY1122403T1 (el)
DK (3) DK3598971T3 (el)
ES (3) ES2980120T3 (el)
HK (1) HK1217170A1 (el)
HR (2) HRP20240812T1 (el)
HU (1) HUE067381T2 (el)
IL (3) IL291831A (el)
MX (2) MX2015009277A (el)
PL (2) PL3598971T3 (el)
PT (3) PT2948140T (el)
RS (1) RS59687B1 (el)
SI (2) SI3598971T1 (el)
WO (1) WO2014116739A1 (el)
ZA (2) ZA201505569B (el)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014209466B2 (en) 2013-01-22 2018-11-08 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses L-4-chlorokynurenine
BR112017024908A2 (pt) * 2015-05-22 2018-07-31 Vistagen Therapeutics Inc usos terapêuticos da 4-cloroquinurenina
EP3347346A1 (en) * 2015-09-08 2018-07-18 Cephalon, Inc. Prodrugs of chlorokynurenines
CA3127220A1 (en) 2018-02-09 2019-08-15 Vistagen Therapeutics, Inc. Synthesis of 4-chlorokynurenines and intermediates
CN109223785A (zh) * 2018-10-29 2019-01-18 中国药科大学 犬尿喹啉酸或其衍生物在制备改善慢性精神应激相关病理损伤药物中的应用
WO2022082100A1 (en) * 2020-10-16 2022-04-21 Vistagen Therapeutics, Inc. Cocrystals of l-4-chlorokynurenine, compositions and therapeutic uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5484814A (en) 1991-02-28 1996-01-16 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
US5360814A (en) 1991-02-28 1994-11-01 Merrell Dow Pharmaceuticals Inc. NMDA antagonists
US5763393A (en) 1996-05-17 1998-06-09 Neurotherapeutics L.P. Neuroactive peptides
TW518218B (en) 1999-05-27 2003-01-21 Merck Patent Gmbh Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
US7250394B2 (en) 2001-08-20 2007-07-31 Maiken Nedergaard Treatment of glial tumors with glutamate antagonists
CA2497867A1 (en) 2002-09-06 2004-03-18 Durect Corporation Delivery of modulators of glutamate-mediated neurotransmission to the inner ear
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
KR20090004950A (ko) 2006-04-12 2009-01-12 프로비오드룩 아게 효소 억제제
EP1903028A1 (en) * 2006-09-22 2008-03-26 Werner Tschollar Conjugates of glutamate and NMDA receptor channel blockers without excito-toxic effects
CA2606658A1 (en) 2006-10-13 2008-04-13 Mike Tyers Compositions and methods for treating neurological disorders or damage
WO2008128985A1 (en) 2007-04-18 2008-10-30 Probiodrug Ag Thiourea derivatives as glutaminyl cyclase inhibitors
WO2009135091A1 (en) * 2008-04-30 2009-11-05 Medivation Technologies, Inc. Use of asenapine and related compounds for the treatment of neuronal or non-neuronal diseases or conditions
US20110190347A1 (en) 2008-08-21 2011-08-04 Richter Gedeon Nyrt. Methods for treating neuropathic pain
EP2421519B1 (en) 2009-04-23 2016-11-02 Universität Zürich Blockers of nmda receptor for the treatment of sickle cell anemia
RU2012101424A (ru) * 2009-06-17 2013-07-27 Таргасепт, Инк. Устранение l-дофа-индуцированной дискинезии с помощью лигандов нейрональных никотиновых рецепторов
CN104777314B (zh) 2009-08-12 2017-01-04 福满代谢组技术有限公司 抑郁症的生物标记物、抑郁症的生物标记物的测定方法、计算机程序及记录介质
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP2338873A1 (en) * 2009-12-22 2011-06-29 Gmeiner, Peter New aminotetraline derivatives
KR101831616B1 (ko) * 2010-06-15 2018-04-04 그뤼넨탈 게엠베하 통증 치료용 약제학적 병용물
US9737531B2 (en) 2012-07-12 2017-08-22 Glytech, Llc Composition and method for treatment of depression and psychosis in humans
AU2014209466B2 (en) 2013-01-22 2018-11-08 Vistagen Therapeutics, Inc. Dosage forms and therapeutic uses L-4-chlorokynurenine
US20160031800A1 (en) 2013-03-14 2016-02-04 Vistagen Therapeutics, Inc. Synthesis of chiral kynurenine compounds and intermediates
JP6603668B2 (ja) 2013-10-28 2019-11-06 ノーレックス インコーポレイテッド Ｎｍｄａ受容体モジュレーター及びプロドラッグ、塩、並びにこれらの使用
BR112017024908A2 (pt) 2015-05-22 2018-07-31 Vistagen Therapeutics Inc usos terapêuticos da 4-cloroquinurenina

Also Published As

Publication number Publication date
US20220409564A1 (en) 2022-12-29
MX2015009277A (es) 2015-12-11
BR112015017535A2 (pt) 2020-02-04
JP2022070894A (ja) 2022-05-13
DK2948140T3 (en) 2017-08-21
SI3598971T1 (sl) 2024-10-30
AU2018253600A1 (en) 2018-11-22
AU2014209466A1 (en) 2015-08-06
JP6804497B2 (ja) 2020-12-23
DK3228313T3 (da) 2019-11-25
PL3598971T3 (pl) 2024-09-09
IL276126A (en) 2020-08-31
AU2018253600B2 (en) 2020-07-09
JP2024069257A (ja) 2024-05-21
EP3598971A1 (en) 2020-01-29
IL240090A0 (en) 2015-09-24
US9993453B2 (en) 2018-06-12
ES2980120T3 (es) 2024-09-30
JP2019023195A (ja) 2019-02-14
CA3128321C (en) 2023-12-05
AU2014209466B2 (en) 2018-11-08
IL291831A (en) 2022-06-01
EP3228313B1 (en) 2019-09-11
EP4385563A3 (en) 2024-08-21
EP4385563A2 (en) 2024-06-19
KR20150109428A (ko) 2015-10-01
CN112933073A (zh) 2021-06-11
HRP20192189T1 (hr) 2020-02-21
KR102257284B1 (ko) 2021-05-28
AU2022221382A1 (en) 2022-09-15
US10980758B2 (en) 2021-04-20
PT2948140T (pt) 2017-08-10
US10632091B2 (en) 2020-04-28
HK1217170A1 (zh) 2016-12-30
US12036198B2 (en) 2024-07-16
EP2948140B1 (en) 2017-05-10
CA3128321A1 (en) 2014-07-31
KR20210063449A (ko) 2021-06-01
AU2022221382B2 (en) 2024-09-19
RS59687B1 (sr) 2020-01-31
ZA201505569B (en) 2017-01-25
NZ710121A (en) 2021-01-29
JP7021298B2 (ja) 2022-02-16
HRP20240812T1 (hr) 2024-09-27
CA2898619C (en) 2021-10-19
US20160158178A1 (en) 2016-06-09
JP2020183400A (ja) 2020-11-12
PT3228313T (pt) 2019-12-17
KR20230003410A (ko) 2023-01-05
US20180369180A1 (en) 2018-12-27
US20190133984A1 (en) 2019-05-09
DK3598971T3 (da) 2024-06-10
EP2948140A1 (en) 2015-12-02
WO2014116739A1 (en) 2014-07-31
ES2635353T3 (es) 2017-10-03
CN113116877A (zh) 2021-07-16
CN105073108A (zh) 2015-11-18
IL240090B (en) 2020-08-31
EP2948140A4 (en) 2016-08-03
AU2020204420A1 (en) 2020-07-23
EP3228313A1 (en) 2017-10-11
KR20230098711A (ko) 2023-07-04
HUE067381T2 (hu) 2024-10-28
ES2751138T3 (es) 2020-03-30
SI3228313T1 (sl) 2019-12-31
US20190125707A1 (en) 2019-05-02
MX2020009966A (es) 2020-10-12
US20180289649A1 (en) 2018-10-11
JP6436913B2 (ja) 2018-12-12
IL276126B (en) 2022-05-01
PL3228313T3 (pl) 2020-03-31
ZA201607581B (en) 2019-04-24
US20150359772A1 (en) 2015-12-17
PT3598971T (pt) 2024-06-20
US10617663B2 (en) 2020-04-14
CN113209068A (zh) 2021-08-06
KR20210149905A (ko) 2021-12-09
US9993450B2 (en) 2018-06-12
EP3598971B1 (en) 2024-03-20
CA2898619A1 (en) 2014-07-31
JP2016505050A (ja) 2016-02-18
CA3216579A1 (en) 2014-07-31
KR102335919B1 (ko) 2021-12-07

Similar Documents

Publication Publication Date Title
CY1124998T1 (el) Ετεροκυκλικες ενωσεις και χρήσεις αυτων
CY1124292T1 (el) Συνθεσεις για τροποποιηση της εκφρασης tau
CY1123845T1 (el) Τοπικα φαρμακευτικα σκευασματα για την αγωγη φλεγμονωδων καταστασεων
CY1122403T1 (el) Μορφες δοσολογιας και θεραπευτικες χρησεις της l-4-χλωροκυνουρενινης
CY1121182T1 (el) Συνθεσεις χρησιμες για τη θεραπεια διαταραχων που σχετιζονται με kit
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
CL2015003731A1 (es) Inhibidores de bromodominios
CL2015001985A1 (es) Compuestos de tiazolcarboxamidas y piridinacarboxamida, inhibidores de quinasa pim.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
EA201692425A1 (ru) Модифицированные биополимеры и способы их получения и использования
TR201901886T4 (tr) DNA-PK inhibitörleri.
EA201591509A1 (ru) Ингибиторы cdc7
MX2015011899A (es) Metodos para el tratamiento de cáncer y prevención de resistencia a los fármacos para el cáncer.
DOP2017000254A (es) Imidazopirazinonas como inhibidores de pde1
CL2016000326A1 (es) Composiciones y método para tratar condiciones asociadas con el complemento
CY1116304T1 (el) Χρηση της βιοτινης για τη θεραπευτικη αγωγη της σκληρυνσης κατα πλακας
EA201692313A1 (ru) Производные индолизина в качестве ингибиторов фосфоинозитид-3-киназ
EA201791454A1 (ru) Лекарственные формы для трансдермального введения
BR112019010131A2 (pt) entrega transdérmica de agentes grandes
BR112018011633A2 (pt) inibidores de aza-benzimidazol de pad4
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
BR112017000730A2 (pt) derivados de pirrolidinona como inibidores de metap-2